Activity of Meclocycline Sulfosalicylate Tested ICID 2006 Against Oral Pathogens RN JONES, TR FRITSCHE, HS SADER, PR RHOMBERG JMI Laboratories, North Liberty, Iowa, USA A M E N D E D A B S T R A C T
¥ Meclocycline SS was markedly superior to
¥ Anaerobes (Table 2) were very susceptible to
meclocycline SS with 23 of 27 strains inhibited
Background: Meclocycline sulfosalicylate (MSS) is a topically-used
streptococci by inhibiting 96.3, 100.0 and
tetracycline derivative that has been utilized for acne vulgaris treatments
and for its other antimicrobial qualities for over three decades.
100.0% of viridans group streptococci, group
Tetracycline-class agents also have non-antimicrobial features that can
A and groups C/G streptococci, respectively
minimize the release of free radicals, reduce expression of cytokines
¥ Table 3 shows the variable effects of tet
and alter degeneration of vascular/connective tissues.
resistance mechanisms on the MICs of five
Methods: Over 20 pathogen groups (265 strains) were tested, including
tetracyclines and a glycylcycline, tigecycline.
35 staphylococci (15 methicillin-resistant), 10
¥ Essentially all tetracyclines were comparable
group streptococci (8 species), 20 §-haemolytic streptococci, 30
to tetracycline HCl against Enterobacteriaceae
MIC population distribution of four tetracyclines tested against
Acinetobacters, 11 Burkholderia cepacia, 10 Moraxella catarrhalis, 10
Neisseria spp., and 27 anaerobic oral flora (10 species). Susceptibility
tests were performed by reference CLSI methods (M7-A7, 2006) with
Antimicrobial Agent ²0.016 0.03 0.06 0.12
¥ Meclocycline SS had the best activity versus
associated interpretive criteria (M100-S16, 2006). Comparison
tetracyclines (four), tigecycline and six other drugs (data not shown)
P. aeruginosa (80% inhibited at 4 mg/L) and
were used. A MSS breakpoint concentration of ²4 mg/L was applied
for comparisons only, that breakpoint most used for other tetracyclines.
Strains with documented tet-mechanisms of resistance were also tested.
Listing of tetracycline and glycylcycline class agent MIC results
tested against S. aureus (5) and E. coli (7) strains with characterized
Results: MSS exhibited equal or greater potency (MIC
to other tetracyclines against streptococci (0.03-0.25 mg/L), staphylococci
¥ B. cepacia was refractory to all tetracyclines,
(0.06-0.12), Neisseria (0.06), most Enterobacteriaceae (1-2 mg/L) and
Tetracycline Doxycycline Minocycline Oxytetracycline Tigecycline
but upper airway colonizers/pathogens such
some non-fermentative bacilli (Acinetobacter spp., MIC50 0.5 mg/L). P.aeruginosa and enterococci were inhibited by MSS with MIC
M. catarrhalis and various Neisseria spp.
at 8-16 mg/L. MSS exhibited cross-resistance with other class agents
tet A-E, K-M, O and S mechanisms. Generally,
MSS was less potent than minocycline and tigecycline versus resistant
Activity of five tetracycline antimicrobial agents tested against 226
recent clinical isolates by reference methodsa. C O N C L U S I O N S Conclusions: At concentrations topically utilized of this non-absorbed
tetracycline (MSS), the vast majority of the tested bacteria were inhibited,
S. aureus, various streptococci and
streptococci (MIC50, 0.03-0.25 mg/L), M.I N T R O D U C T I O N
(MIC50, 0.06 mg/L), and Neisseria spp.
Meclocycline sulfosalicylate (SS) is a topically applied tetracycline derivative
that has been utilized for acne vulgaris treatment and for its other antimicrobial
qualities for over three decades. Tetracycline-class agents also have non-
antimicrobial features that can minimize the release of free radicals, reduce
¥ By testing strains possessing tet
expression of cytokines and alter degeneration of vascular/connective
tissues. To assess the continuing spectrum of meclocycline SS and older
peer drugs (doxycycline, minocycline, oxytetracycline and tetracycline HCl),
considered refractory to the antimicrobial
all were tested against a wide variety of contemporary pathogens and upper
airway or oral flora. Reference methods were utilized with commonly applied
action of other tetracyclines would also be
M AT E R I A L S A N D M E T H O D S
The susceptibility testing methods were reference procedures from the
tetracycline derivatives tested, appears to
Clinical and Laboratory Standards Institute (CLSI) documents M7-A7 (2006)
and M11-A6 (2004). MIC interpretations followed CLSI M100-S16 (2006),
where available. For comparison purposes, ²4 mg/L was the breakpoint
for susceptibility applied to all tetracycline derivatives.
in its class, and appears appropriate for
Organisms tested (n = 265) were generally recent clinical isolates or index
use against pathogens associated with oral
type strains from the American Type Culture Collection (ATCC). These
mucositis by virtue of its anti-inflammatory
included: S. aureus (25; 10 oxacillin-resistant [MRSA]), S. epidermidis (10;
E. faecalis (10), viridans group streptococci (80; 8
species), S. pyogenes (10), serogroups C and G §-haemolytic streptococci
(10), Enterobacteriaceae (30; 3 species), P. aeruginosa (10), A. baumanniiB. cepacia (11), M. catarrhalis (10), Neisseria spp. (10; 5 species) and
27 anaerobic isolates (Tables 1 and 2). Also, a collection of 12 strains of
A C K N O W L E D G E M E N T S S. aureus or E. coli having well characterized tetracycline resistance
We are thankful to the following individuals for the contribution of the bacterial
strains used in the anaerobe component of this protocol: R. Darveau and
P. Braham (University of Washington Department of Pediatrics); D. Drake
and B. Olson (University of Iowa Department of Endodontics); D. Snydman
and L. McDermott (Tufts University School of Medicine); and P. Bradford
¥ Meclocycline SS and minocycline were the
most active tetracyclines tested against the
R E F E R E N C E S
Clinical and Laboratory Standards Institute. (2006). Performance standardsfor antimicrobial susceptibility testing, 16th informational supplement M100-
at ²4 mg/L of the tetracyclines, best for
Clinical and Laboratory Standards Institute. (2006). Methods for dilution
Criteria as published by the CLSI [2006], where available. A breakpoint of ²4 mg/L for susceptibility was applied to all tetracyclines for
antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed.Approved Standard M7-A7. Wayne, PA: CLSI, 2006.
20 décembre 2007 N° 15 Le mot du Président Vous avez été nombreux à faire confiance à votre président et à soutenir les instances dirigeantesde l’Epaulette pour mener à bien des projets partagés, pour notre association. Ces derniers mois,beaucoup d’entre vous se sont investis à fond en vue d’atteindre l’objectif de recrutement dontL’Epaulette a besoin pour montrer sa
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document and/or the action you should take, you should immediately consult your stockbroker, bank manager, solicitor or other independent financial advisor duly authorised under the Financial Services and Markets Act 2000 (as amended). TRICOR PLC (incorporated and regi